PBLA — Panbela Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.17m
- $7.42m
Annual income statement for Panbela Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.32 | 5.65 | 10 | 34.1 | 25.6 |
| Operating Profit | -4.32 | -5.65 | -10 | -34.1 | -25.6 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.62 | -5.06 | -10.6 | -35 | -25.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.2 | -4.77 | -10.1 | -34.9 | -25.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.2 | -4.77 | -10.1 | -34.9 | -25.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.2 | -4.77 | -10.1 | -34.9 | -25.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -26,106 | -15,007 | -20,776 | -40,753 | -235 |